ArticleImmunologic research2026
Diosmetin alleviates retinal ischemia-reperfusion injury through SIRT1-mediated suppression of oxidative stress, inflammation, and PANoptosis.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRetinal ischemia-reperfusion (RI/R) injury causes vision loss and lacks effective treatments. The role of diosmetin (DIO) in this condition, particularly through the SIRT1/Nrf2 pathway and its effect on PANoptosis, is unknown.
methodsAn in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model was developed using R28 retinal precursor cells, while an in vivo rat model of retinal ischemia/reperfusion (RI/R) was created through transient intraocular pressure elevation. DIO was administered in vitro, at the onset of reperfusion, and in vivo, via intraperitoneal injection. Cell viability, proliferation, oxidative stress markers, inflammatory cytokines, and PANoptosis-related protein expression were assessed. The role of SIRT1 was confirmed using siRNA knockdown in vitro and the pharmacological inhibitor EX527 in vivo.
resultsDIO treatment notably enhanced cell viability and proliferation in OGD/R-injured R28 cells, while also maintaining retinal structure and neuronal survival in RI/R-injured rats. DIO stimulated the SIRT1/Nrf2 pathway, evidenced by elevated levels of SIRT1, nuclear Nrf2, and HO-1 expression. This activation diminished oxidative stress, evidenced by lower ROS and MDA levels and higher SOD, CAT, and GSH levels, while also reducing inflammation, as indicated by decreased TNF-α, IL-1β, and IL-18. Consequently, DIO inhibited PANoptosis by downregulating key markers of apoptosis (cleaved caspase-3, BAX), pyroptosis (NLRP3, GSDMD), and necroptosis (p-RIPK3, p-MLKL). The beneficial effects of DIO, including neuroprotection, antioxidant activity, anti-inflammation, and anti-PANoptosis, were entirely nullified by SIRT1 knockdown or inhibition.
conclusionDIO protects against retinal I/R injury by activating SIRT1/Nrf2 to inhibit oxidative stress, inflammation, and PANoptosis, highlighting its therapeutic potential.
Indexed as
Identifiers
42570121What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.